Jonah Ng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jonah Ng has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Jaydeep Roy
Center of Excellence for Brain Health and Neurotechnology, Academy of Life and Natural Sciences, Xi'an Jiaotong-Liverpool University, Suzhou, China; School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong, China
1 shared publication - Ka Chun Tsui
Center of Excellence for Brain Health and Neurotechnology, Academy of Life and Natural Sciences, Xi'an Jiaotong-Liverpool University, Suzhou, China; School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong, China
1 shared publication - Lee Wei Lim
DrLim Neuromodulation Lab, Department of Biosciences and Bioinformatics, School of Science, Xi’an Jiaotong-Liverpool University, Suzhou 215123, China
1 shared publication - Man-Lung Fung
School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China
1 shared publication
Latest Publications
- Open Access
- 25 June 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (13) , 6841
Regulation of Melatonin and Neurotransmission in Alzheimer’s Disease
Alzheimer’s disease is a neurodegenerative disorder associated with age, and is characterized by pathological markers such as amyloid-beta plaques and neurofibrillary tangles. Symptoms of AD include cognitive impairments, anxiety and depression. It has also been shown that individuals with AD have impaired neurotransmission, which may result from the accumulation of amyloid plaques and neurofibrillary tangles. Preclinical studies showed that melatonin, a monoaminergic neurotransmitter released from the pineal gland, is able to ameliorate AD pathologies and restore cognitive impairments. Theoretically, inhibition of the pathological progression of AD by melatonin treatment should also restore the impaired neurotransmission. This review aims to explore the impact of AD on neurotransmission, and whether and how melatonin can enhance neurotransmission via improving AD pathology.
- 25 June 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (13) , 6841
Open AccessRegulation of Melatonin and Neurotransmission in Alzheimer’s Disease
Alzheimer’s disease is a neurodegenerative disorder associated with age, and is characterized by pathological markers such as amyloid-beta plaques and neurofibrillary tangles. Symptoms of AD include cognitive impairments, anxiety and depression. It has also been shown that individuals with AD have impaired neurotransmission, which may result from the accumulation of amyloid plaques and neurofibrillary tangles. Preclinical studies showed that melatonin, a monoaminergic neurotransmitter released from the pineal gland, is able to ameliorate AD pathologies and restore cognitive impairments. Theoretically, inhibition of the pathological progression of AD by melatonin treatment should also restore the impaired neurotransmission. This review aims to explore the impact of AD on neurotransmission, and whether and how melatonin can enhance neurotransmission via improving AD pathology.